Understanding sarcopenia : causes, mechanisms and consequences

Alfonso J. Cruz-Jentoft Hospital Universitario Ramón y Cajal Madrid (Spain)

Muscle wasting is a problem

«Take an old person suffering a process of physiological atrophy due to advanced age, of his/her muscular elements, for instance of the muscles of the legs, where it usually happens, causing total or partial paraplegia. Why not calling it wasting, degeneration with no reincorporation?»


Lozano E. Enfermedades en los viejos y crónicos. Madrid: G Juste, 1899.




Starting point

- Sarcopenia is a medical condition not yet broadly recognized by the international medical community. Discussions on definition, diagnostic methods and interventions are ongoing.
- Sarcopenia is in the process to receive an ICD-10 code and is most certainly underdiagnosed.

Sarcopenia: first steps






- "No decline with age is as dramatic or potentially more significant than the decline in lean body mass. In fact, there may be no single feature of age-related decline more striking than the decline in lean body mass in affecting ambulation, mobility, energy intake, overall nutrient intake and status, independence and breathing.
- I suggested that if this phenomenon were to be taken seriously, we had to give it a name. I proposed that the name for this phenomenon should be derived from the Greek."

Sarcopenia: the concept




Sarcopenia is a threat in old age

- Linked with the geriatric evolving concept of "frailty"
- Related with weight loss, malnutriton and cachexia
- The main consequences are disability, dependence and death




Human muscles


- 600 muscles in human body
- Skeletal muscles:40-45% of total body mass
- 55% of skeletal muscle mass in lower limbs
- 50% of total body protein is in muscles



Frontera WR et al. In: Physical Medicine&Rehabilitation. DeLisa JA (ed). LWW 2005

Low skeletal body mass





Janssen I et al. Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability. J Am Geriatr Soc 2002











REPORT

Sarcopenia: European consensus on definition and diagnosis

Report of the European Working Group on Sarcopenia in Older People Alfonso J. Cruz-Jentoft¹, Jean Pierre Baeyens², Jürgen M. Bauer³, Yves Boirie⁴, Tommy Cederholm⁵, Francesco Landi⁶, Finbarr C. Martin⁷, Jean-Pierre Michel⁸, Yves Rolland⁹, Stéphane M. Schneider¹⁰, Eva Topinková¹¹, Maurits Vandewoude¹², Mauro Zamboni¹³


EWGSOP Definition of Sarcopenia

Sarcopenia is a <u>syndrome</u> characterized by <u>progressive</u> and generalized loss of skeletal muscle <u>mass</u> and <u>strength</u> with a risk of <u>adverse outcomes</u> such as physical disability, poor quality of life and death.

CRITERIA FOR THE DIAGNOSIS OF SARCOPENIA

progressive

A lifelong model of sarcopenia



Sayer AA et al. The developmental origins of sarcopenia. J Nutr Health Aging 2008

Birth weight and muscle strength

Study author,		Mean age			Effect	%
year (sex)	n (y)			size (95% CI)	Weig
Barr 2010 (B)	574 9).3			0.42 (0.04, 0.80)	11.60
Ortega 2009 (M)	818 1	5.3	-		-0.16 (-0.99, 0.67)	6.47
Ortega 2009 (F)	983 1	5.4		+	0.39 (-0.11, 0.90)	9.98
Ericson 1998 (M)	802 1	7.7	-	-	1.22 (0.54, 1.90)	7.88
Kuzawa 2010(B)	1722 2	20.9		•	0.98 (-1.33, 3.29)	1.35
Ridgway 2011 (B)	783 2	5.6	-		1.17 (0.27, 2.07)	5.87
Martorell 1998 (B)	495 2	29.7	-	<u>-</u>	0.11 (-1.09, 1.31)	4.01
Inskip 2007 (F)	1352 3	80.6	- -	-	1.11 (0.60, 1.62)	9.95
Ridgway 2009 (B)	4273 3	31.0			1.40 (0.93, 1.87)	10.4
te Velde 2004 (B)	273 3	6.6		<u> </u>	-0.02 (-2.55, 2.51)	1.14
Kuh 2002(B)	2830 5	53.0			1.73 (0.97, 2.49)	7.12
Yliharsila 2007 (B)	1877 6	51.5		-	0.70 (-0.03, 1.43)	7.41
Robinson 2008 (B)	2983 6	6.2		-	0.89 (0.46, 1.32)	10.9
Sayer 1998 (B)	716 6	37.5	-	-	1.28 (0.37, 2.19)	5.81
Overall (I -squared :	= 56.2%, p	o = 0.005)	<	\triangleright	0.86 (0.58, 1.15)	100.0
		3.29	0	3.2	29	
Char	nao in m		(kg) por 1 kg	increase in birt	h woight	

Dodds R, et al. Birth weight and muscle strength: a systematic review and meta-analysis. J Nutr Health Aging. 2012;16(7):609-15.


EWGSOP Definition of Sarcopenia

Sarcopenia is a <u>syndrome</u> characterized by <u>progressive</u> and generalized loss of skeletal muscle <u>mass</u> and <u>strength</u> with a risk of <u>adverse outcomes</u> such as physical disability, poor quality of life and death.

CRITERIA FOR THE DIAGNOSIS OF SARCOPENIA


geriatric syndrome

The complexity of geriatric syndromes




Olde Rikkert MG et al. Geriatric syndromes: Medical misnomer or progress in geriatrics? Neth J Med 2003;61:83–87.

Modeling geriatric syndromes



Decker S, Sausville EA. Preclinical modeling of combination treatments: Fantasy or requirement? Ann NY Acad Sci 2005;1059:61–69.

Sarcopenia is a geriatric syndrome



Cruz-Jentoft AJ et al. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Met Care 2010.

EWGSOP Definition of Sarcopenia

Sarcopenia is a <u>syndrome</u> characterized by <u>progressive</u> and generalized loss of skeletal muscle <u>mass</u> and <u>strength</u> with a risk of <u>adverse outcomes</u> such as physical disability, poor quality of life and death.

CRITERIA FOR THE DIAGNOSIS OF SARCOPENIA

adverse outcomes

Sarcopenia increases mortality

Table 2. Association between sarcopenia and all-cause mortality, after adjustment for various confounders (hazard ratios and 95% confidence intervals)

	Unadjusted	Model 1	Model 2	Model 3			
	Hazard ratio (95% confidence interval)						
Sarcopenia	2.95 (1.44–6.04)	2.89 (1.40–5.96)	2.40 (1.07–5.42)	2.32 (1.01–5.43)			
Age		1.15 (0.93–1.42)	1.08 (0.85–1.36)	1.12 (0.87–1.43)			
Gender (female)		0.55 (0.29-1.03)	0.49 (0.25-0.99)	0.49 (0.23-1.04)			
Education			0.87 (0.72–1.04)	0.87 (0.72-1.05)			
ADL impairment			1.91 (1.29–2.83)	1.75 (1.20-2.56)			
Body mass index			0.92 (0.86-0.99)	0.93 (0.86-1.01)			
Hypertension				0.60 (0.26-1.35)			
Congestive heart failure				6.71 (0.70-64.1)			
COPD				1.46 (0.50-4.21)			
Number of diseases				1.29 (0.92-1.80)			
TNF-α				0.99 (0.85-1.15)			

Model 1: adjusted for age, gender.

Model 2: adjusted for age, gender, education, ADL impairment, body mass index.

Model 3: adjusted for age, gender, education, ADL impairment, body mass index, hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), number of diseases, $TNF-\alpha$.


Age, education, ADL impairment, body mass index, number of diseases, TNF-a was treated as a continuous variable.

Landi F et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 2013


EWGSOP Definition of Sarcopenia

Sarcopenia is a <u>syndrome</u> characterized by <u>progressive</u> and generalized loss of skeletal muscle <u>mass</u> and <u>strength</u> with a risk of <u>adverse outcomes</u> such as physical disability, poor quality of life and death.

CRITERIA FOR THE DIAGNOSIS OF SARCOPENIA




Risk of poor physical performance or physical disability in older adults with low muscle mass



Manini TM, Clark BC. Dynapenia and Aging: An Update. J Gerontol A Biol Sci Med Sci 2011


Risk of poor physical performance or physical disability in older adults with low muscle strength



Manini TM, Clark BC. Dynapenia and Aging: An Update. J Gerontol A Biol Sci Med Sci 2011

EWGSOP Conceptual Stages of Sarcopenia

Sarcopenia staging, which reflects the severity of the condition, is a concept that can help guide clinical management of the condition.



EWGSOP

Secondary

Activity related Bed rest Sedentary lifestyle Deconditioning

Primary Age-related

Disease related


Advanced organ failure Inflamatory diseases Malignancy Endocrine diseases

Nutrition related

Inadequate diet Malabsortion Gastrointestinal disorders Drug induced anorexia


Sarcopenia, cachexia, inflammation

- Systemic inflammation seems to be linked to muscle wasting
- Some degree of inflammation may be present in sarcopenia
- Inflammation is key in the pathogenesis of cachexia
 - CRP (>5.0 mg/l, IL-6 >4.0 pg/ ml)
- Low muscle mass and strength are part of the definition of cachexia



Evans WJ et al. Cachexia: A new definition. Clin Nutr 2008. Muscaritoli M et al. Consensus definition of sarcopenia, cachexia and pre-cachexia. Clin Nutr 2010. Rolland Y et al. Cachexia versus sarcopenia. Curr Opin Clin Nutr Met Care 2011.

Suggested measures to diagnose sarcopenia





MUSCLE STRENGTH

Handgrip strength

Knee flexion-extension PEF



PHYSICAL PERFORMANCE

SPPB Gait speed Get up&Go Stair climbing

Sarcopenia with limited mobility

Society for Sarcopenia, Cachexia and Wasting Disorders

Sarcopenia with limited mobility is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6 minute walk.

Muscle loss: lean appendicular mass (corrected for height squared) >2 SD below healthy persons between 20 to 30 years of age of the same ethnic group.

Limitation in mobility not clearly attributable to the direct effect of specific disease such as peripheral vascular disease, or central or peripheral nervous system disorders, dementia, or cachexia.

Morley JE et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011

Sarcopenia and physical frailty

Shrinking: unintentional weight loss, sarcopenia

Weakness

Poor endurance, exhaustion

Slowness

Low activity

Positive for frailty phenotype: 3 or more criteria present Intermediate or prefrail: 1 or 2 criteria present Sarcopenia may be a more practical concept than physical frailty in the quest to reduce disability

Fried L et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001.